Concomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature.

abstract：:Most human myeloid leukemias express both class I and class II HLA and it has been postulated that leukemia-associated peptides are presented by those molecules. It is possible, however, that leukemia cells escape the immune surveillance by lacking expression of "costimulatory" molecules required for activating the im...

journal_title：Leukemia & lymphoma

authors： Matsumoto K,Anasetti C

更新日期：1999-11-01 00:00:00

abstract：:A possible role for DNA mismatch repair defects and microsatellite instability (MSI) in the pathogenesis of a number of B-cell lymphoproliferative disorders has recently been debated. To gain further insight into the impact of MSI on B-CLL, we evaluated samples from a series of 982 patients using the mono-satellite ma...

journal_title：Leukemia & lymphoma

authors： Sellick GS,Lubbe SJ,Matutes E,Catovsky D,Houlston RS

更新日期：2007-07-01 00:00:00

abstract：:BRAF mutations have been shown to occur at a high frequency in melanoma and thyroid cancer, but also at lower frequencies in hematological malignancies. To assess the potential role of BRAF, we have sequenced exons 11 and 15 of BRAF in 138 cases with chronic lymphocytic leukemia (CLL) and 32 cases of B-cell prolymphoc...

journal_title：Leukemia & lymphoma

authors： Jebaraj BM,Kienle D,Bühler A,Winkler D,Döhner H,Stilgenbauer S,Zenz T

更新日期：2013-06-01 00:00:00

abstract：:In chronic myeloid leukemia (CML), experimental studies using synthetic peptides identical to the bcr-abl fusion region have revealed the capability of specific peptides to bind to human leukocyte antigen (HLA) class I molecules (HLA-A2, A3, A11, B8) and class II molecules (HLA-DR1, DR2, DR3, DR4 and DR11). Individual...

journal_title：Leukemia & lymphoma

authors： Chhaya SU

更新日期：2006-02-01 00:00:00

abstract：:Sarcopenia is associated with treatment-related complications and shorter overall survival in patients with cancer. Psoas area indices were calculated for 121 patients with lymphoma who underwent autologous transplant. Controlling for age, body mass index, comorbidities and performance status for the 73 men included, ...

journal_title：Leukemia & lymphoma

authors： Caram MV,Bellile EL,Englesbe MJ,Terjimanian M,Wang SC,Griggs JJ,Couriel D

更新日期：2015-01-01 00:00:00

abstract：:Secondary malignancies represent a relevant complication of chemotherapy employed for a previous cancer. Acute leukemias represent the most frequent secondary malignancy in the first decade following primary neoplasms; secondary leukemias are generally myeloid and can be preceeded by a myelodysplastic syndrome. The bi...

journal_title：Leukemia & lymphoma

authors： Pagano L,Pulsoni A,Mele L,Leone G

更新日期：2000-11-01 00:00:00

abstract：:We describe a patient with natural killer (NK)/T cell lymphoma who relapsed after autologous peripheral blood stem cell transplantation (auto-PBSCT) and was successfully treated with Escherichia coli (E. coli) and Erwinia L-asparaginase. A 38-year-old male patient with ulcerated tumor at the left thigh was diagnosed a...

journal_title：Leukemia & lymphoma

authors： Matsumoto Y,Nomura K,Kanda-Akano Y,Fujita Y,Nakao M,Ueda K,Horiike S,Yokota S,Kusuzaki K,Kitoh T,Watanabe A,Taniwaki M

更新日期：2003-05-01 00:00:00

abstract：:Myeloperoxidase (MPO) is an abundant heme protein found in granulocytes and monocytes, which plays an important role in host defense against infection. MPO enzyme activity as determined by light microscopic cytochemistry has long been an important marker used in the diagnosis of acute leukemias and other hematopoietic...

journal_title：Leukemia & lymphoma

authors： Austin GE,Chan WC,Zhao W,Racine M

更新日期：1994-10-01 00:00:00

abstract：:The B cell non-Hodgkin's lymphomas (NHL-B) are a common, but heterogeneous group of human lymphoid neoplasms, consisting of monoclonal populations of neoplastic B lymphocytes demonstrating non-random chromosomal abnormalities, often associated with proto-oncogene translocations. Clinically and pathologically, these ly...

journal_title：Leukemia & lymphoma

authors： Ford RJ,Tamayo A,Li DJ,Cabanillas F

更新日期：1993-01-01 00:00:00

abstract：:Bone marrow toxicity is a great challenge for physicians treating patients with non-Hodgkin's lymphoma (NHL) and prescribed chemotherapy. Granulocyte colony-stimulating factor (G-CSF) prevents myelotoxicity, but the optimal timing and scheduling of G-CSF administration has not been ascertained. We investigated leukocy...

journal_title：Leukemia & lymphoma

authors： Sawada KI,Sato N,Kohno M,Hannda H,Yasukouchi T,Tanngo M,Hirayama A,Koike T

更新日期：1995-12-01 00:00:00

abstract：:Recent advances in the treatment of patients with non-Hodgkin lymphoma have driven a paradigm shift from standard chemotherapy to an ever-expanding choice of targeted agents and combinations. As an orally bioavailable immunomodulator with antineoplastic, immunologic, and antiproliferative activity in B-cell lymphoma, ...

journal_title：Leukemia & lymphoma

authors： Galanina N,Petrich A,Nabhan C

更新日期：2016-07-01 00:00:00

abstract：:Thymosin β4 (Tβ4) was originally isolated as a thymic hormone from calf thymosin fraction 5 which exhibited both immune and endocrine functions in vivo and in vitro. Tβ4 is a ubiquitous peptide located in various tissues of mammalian species and other vertebrate classes. Recent studies on the molecular cloning and seq...

journal_title：Leukemia & lymphoma

authors： Kudo J,Shimamura R,Ishibashi H,Niho Y

更新日期：1991-01-01 00:00:00

abstract：:The human analogue of the mouse double minute-2 (MDM-2) protein binds to p53 protein and abrogates its tumor-suppressing activity. MDM-2 overexpression may represent an alternative mechanism to p53 mutation for escaping the p53-mediated growth control. Interestingly, multiple MDM-2 protein isoforms have been described...

journal_title：Leukemia & lymphoma

authors： Bueso-Ramos CE,Manshouri T,Haidar MA,Huh YO,Keating MJ,Albitar M

更新日期：1995-03-01 00:00:00

abstract：:Anthracyclines have contributed significantly to the increased cure rate in pediatric oncology. Cardiac toxicity is an important late effect after anthracycline treatment and is thought to occur by reactive oxygen species mediated cardiac damage. We hypothesized that deactivating variants of superoxide dismutase II (S...

journal_title：Leukemia & lymphoma

authors： Rajić V,Aplenc R,Debeljak M,Prestor VV,Karas-Kuzelicki N,Mlinaric-Rascan I,Jazbec J

更新日期：2009-10-01 00:00:00

abstract：:We evaluated the safety and biologic activity of the BH3 mimetic protein, navitoclax, combined with rituximab, in comparison to rituximab alone. One hundred and eighteen patients with chronic lymphocytic leukemia (CLL) were randomized to receive eight weekly doses of rituximab (arm A), eight weekly doses of rituximab ...

journal_title：Leukemia & lymphoma

authors： Kipps TJ,Eradat H,Grosicki S,Catalano J,Cosolo W,Dyagil IS,Yalamanchili S,Chai A,Sahasranaman S,Punnoose E,Hurst D,Pylypenko H

更新日期：2015-01-01 00:00:00

abstract：:In this study we compared rates of apoptosis, survival and metabolic activity from CML peripheral blood neutrophils with peripheral blood and bone marrow neutrophils from healthy volunteer donors and studied the influence of the disease stage and of cytokines including G-CSF, GM-CSF and IL-1beta on these parameters. Q...

journal_title：Leukemia & lymphoma

authors： Gisslinger H,Kurzrock R,Wetzler M,Tucker S,Kantarjian H,Robertson B,Talpaz M

更新日期：1997-03-01 00:00:00

abstract：:Expression of T, sialosyl-T and disialosyl-T antigens on normal blood and bone marrow cells as well as transformed cells was examined using specific monoclonal antibodies and multidimensional flow cytometry. Both anti-sialosyl-T (QSH1) and anti-disialosyl-T (QSH2) monoclonal antibodies aggregated erythrocytes. The ant...

journal_title：Leukemia & lymphoma

authors： Muroi K,Amemiya Y,Sievers EL,Miura Y,Hakamori SI,Loken MR

更新日期：1997-05-01 00:00:00

abstract：:In 90 splenectomized patients with active HCL, this multi-institutional intergroup study showed that as compared to alpha interferon (aIF), pentostatin resulted in a higher incidence of response, but the difference was not statistically significantly. Pentostatin-induced remissions occurred significantly faster and su...

journal_title：Leukemia & lymphoma

authors： Rai KR

更新日期：1994-01-01 00:00:00

abstract：:The immune cell composition of the follicular lymphoma (FL) tumor microenvironment is increasingly recognized as an important determinant for clinical outcome. Here, we explored frequency and distribution of dendritic cell (DC) subtypes in relation to regulatory T cells (Treg) by immunohistochemistry in lymph node bio...

journal_title：Leukemia & lymphoma

authors： Chevalier N,Mueller M,Mougiakakos D,Ihorst G,Marks R,Schmitt-Graeff A,Veelken H

更新日期：2016-09-01 00:00:00

abstract：:Arsenic trioxide, believed to be a carcinogen and a teratogen, has found its niche in the treatment of acute promyelocytic leukemia (APL). APL is a disease affecting young patients. Post-treatment fertility and outcome of pregnancy are always a concern in a disease with high cure rates. We report a case series of six ...

journal_title：Leukemia & lymphoma

authors： Gupta S,Bagel B,Gujral S,Subramanian PG,Khattry N,Menon H,Nair R

更新日期：2012-11-01 00:00:00

abstract：:This study was designed to investigate the immunomodulatory effect of low-dose IL-2 therapy (100 microg/day for 3 weeks) on interferon (IFN), tumor necrosis factor (TNF) production in vivo and in vitro and on the expression of IL-2Ralpha/beta and soluble form of IL-2Ralpha. Patients enrolled in the study suffered from...

journal_title：Leukemia & lymphoma

authors： Dmoszyńska A,Kandefer-Szerszeń M,Roliński J,Legieć W,Kamińska T

更新日期：1999-10-01 00:00:00

abstract：:Chronic exposure to high concentrations of benzene is associated with an increased incidence of myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Studies of patients occupationally exposed to benzene show a pattern of cytogenetic aberrations involving loss of all or part of chromosomes 5 and/or 7 as...

journal_title：Leukemia & lymphoma

authors： Stillman WS,Varella-Garcia M,Irons RD

更新日期：1999-10-01 00:00:00

abstract：:Hodgkin lymphoma (HL) has become a highly curable malignancy even in advanced stages when treated adequately. However, relapsed or refractory disease and treatment-related toxicity constitute a significant clinical challenge. Innovative approaches are thus needed to improve treatment of these mainly young patients. In...

journal_title：Leukemia & lymphoma

authors： Bröckelmann PJ,Borchmann P,Engert A

更新日期：2016-09-01 00:00:00

abstract：:Analysis of leukemia-specific and leukemia-associated markers following standard or high-dose treatments is crucial in order to evaluate the efficacy of therapeutic strategies. During the last decade, several techniques have been proposed and used for detecting minimal residual disease (MRD). Each approach is characte...

journal_title：Leukemia & lymphoma

authors： Carlo-Stella C,Mangoni L,Dotti GP,Rizzoli V

更新日期：1995-01-01 00:00:00

abstract：:It is unknown whether rituximab increases the risk of second primary malignancies (SPMs) in patients with diffuse large cell B-cell lymphoma (DLBCL). We assessed SPMs in DLBCL patients diagnosed between 1996 and 2014 in comparison with the general Israeli population and dependent on rituximab treatment. Jewish patient...

journal_title：Leukemia & lymphoma

authors： Neeman Y,Perry C,Silverman B,Waintraub N,Avivi I

更新日期：2020-11-01 00:00:00

abstract：:Reprimo (RPRM) is a novel tumor suppressor. However, the expression and molecular function of RPRM in pediatric acute myeloid leukemia (AML) is still unknown. We observed hypermethylation of the RPRM promoter in 8/11 leukemia cell lines and in 44.8% (47/105) of pediatric AML samples compared with 6.7% (2/30) of contro...

journal_title：Leukemia & lymphoma

authors： Tao YF,Li ZH,Wang NN,Fang F,Xu LX,Pan J

更新日期：2015-01-01 00:00:00

abstract：:The aberrant expression of myeloid antigen CD66 on acute B-lymphoblastic leukemia (B-ALL) cells is a well-documented phenomenon. CD66a is a major subtype of the CD66 family which plays a dual role in different cancers, and the contradictory effect may depend on the isoform ratio of CD66a-4L to CD66a-4S. Although the a...

journal_title：Leukemia & lymphoma

authors： Zhao W,Zhang Y,Liu D,Zhong L,He Q,Zhao Y

更新日期：2015-01-01 00:00:00

abstract：:Myeloablative doses of busulfan (Bu) with fludarabine (Flu) have reduced toxicity, however, limited by an increased relapse rate. We aimed to improve outcome of Flu-Bu regimen by augmentation with thiotepa (TT) (10 mg/kg). Eighty-nine patients with AML, 44 patients conditioned with Flu-Bu (group 1), and 45 patients au...

journal_title：Leukemia & lymphoma

authors： Sheth V,Nachmias B,Grisariu S,Avni B,Or R,Shapira M

更新日期：2019-03-01 00:00:00

abstract：:Treatment of a 74 year old patient with chronic myelogenous leukemia (CML) with busulphan resulted in an abrupt and pronounced decrease of the white blood cell (WBC) count with restoration of normal peripheral blood cell morphology and regression of splenomegaly. The Philadelphia positive (Ph+) clone was however still...

journal_title：Leukemia & lymphoma

authors： Michaeli J,Fibach E,Rachmilewitz EA

更新日期：1993-10-01 00:00:00

abstract：:In the rituximab era, several large studies have suggested that full-dose rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) might be the best treatment for patients with diffuse large B-cell lymphoma (DLBCL) aged 60 years and older. However, it remains unclear whether this is also the c...

journal_title：Leukemia & lymphoma

authors： Meguro A,Ozaki K,Sato K,Oh I,Fujiwara S,Hosonuma R,Sasazaki M,Kikuchi Y,Hirata Y,Yamamoto C,Uesawa M,Kobayashi H,Matsu H,Okabe H,Uehara E,Nishikawa A,Tatara R,Hatano K,Yamamoto C,Matsuyama T,Toshima M,Ueda M,O

更新日期：2012-01-01 00:00:00